|
KMID : 0882420190940060485
|
|
Korean Journal of Medicine
2019 Volume.94 No. 6 p.485 ~ p.494
|
|
|
Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement
|
|
Chin Sang-Ouk
Ku Cheol-Ryong
Kim Byung-Joon
Kim Sung-Woon
Park Kyeong-Hye
Song Kee-Ho
Oh Seung-Joon
Yoon Hyun-Koo
Lee Eun-Jig
Lee Jung-Min
Lim Jung-Soo
Kim Jung-Hee
Kim Kwang-Joon
Jin Heung-Yong
Kim Dae-Joong
Lee Kyung-Ae
Moon Seong-Su
Lim Dong-Jun
Shin Dong-Yeop
Kim Se-Hwa
Kwon Min-Jeong
Kim Ha-Young
Kim Jin-Hwa
Kim Dong-Sun
Kim Jong-Hwa
|
|
|
Abstract
|
|
|
|
Acromegaly is a chronic disorder caused by excessive growth hormone (GH) secretion. In most cases, the excess GH originates from GH-producing pituitary adenomas. Surgery is the preferred first-line treatment for patients with acromegaly, but medical management is considered when the disease persists after surgery or in cases where patients refuse surgery or are poor candidates for surgery. Somatostatin analogues are commonly used to treat acromegaly. The Korean Endocrine Society and the Korean Neuroendocrine Study Group have developed a position statement for the use of somatostatin analogues in the medical treatment of acromegaly. This position statement is based on evidence from the current literature and expert opinions. In the case of discrepancies among expert opinions, the experts voted to determine the recommended approach.
|
|
|
KEYWORD
|
|
|
Acromegaly, Somatostatin, Octreotide, Lanreotide, Pasireotide
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
  
|